StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.16 (-26.87%)

Close on Nov 16, 2026Market cap $259.49KP/E –Yield –

Virax Biolabs total assets

Total assets on the balance sheet at the end of each period.

Virax Biolabs's total assets was $8.32M at Mar 31, 2026. For fiscal 2026 it was $8.32M, up 29.5% from the year before. The highest annual figure on record is $9.81M in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2026Mar 31, 2026$8.32M+29.5%
FY2025Mar 31, 2025$6.43M+17.2%
FY2024Mar 31, 2024$5.48M-44.1%
FY2023Mar 31, 2023$9.81M+20046.2%
FY2022Mar 31, 2022$48.71K+22.9%
FY2021Mar 31, 2021$39.62K–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ1 2026Mar 31, 2026$8.32M+16991.9%
Q4 FY2025CQ1 2025Mar 31, 2025$6.43M+16121.0%
Q4 FY2024CQ1 2024Mar 31, 2024$5.48M–
Q4 FY2023CQ1 2023Mar 31, 2023$9.81M–
Q4 FY2022CQ1 2022Mar 31, 2022$48.71K–
Q4 FY2021CQ1 2021Mar 31, 2021$39.62K–

More Virax Biolabs figures

See a number that looks wrong?